Eddy Kamryn T, Dutra Lissa, Bradley Rebekah, Westen Drew
Department of Psychology, Center for Anxiety and Related Disorders, Boston University, USA.
Clin Psychol Rev. 2004 Dec;24(8):1011-30. doi: 10.1016/j.cpr.2004.08.004.
A number of qualitative and meta-analytic reviews point to the efficacy of psychotherapeutic and pharmacological interventions for obsessive-compulsive disorder (OCD). In this article, we report a multidimensional meta-analysis of psychological and pharmacological treatment studies for OCD published between 1980 and 2001, examining a range of variables not previously meta-analyzed, including exclusion rates and exclusion criteria, percent of patients improved or recovered post-treatment, mean post-treatment symptomatology, and long-term outcome. These additional metrics provide a more nuanced view of the strengths and limitations of the existing data and their implications for clinical practice. Behavioral and cognitive-behavioral therapy, and a range of pharmacological interventions, lead to substantial improvement for the average patient, with individual psychotherapies and clomipramine and other Serotonin reuptake inhibitors faring best across multiple metrics. However, OCD symptoms persist at moderate levels even following adequate treatment course, and no replicable data are available on maintenance of gains for either form of treatment at 1 year or beyond. Future research should track recruitment and exclusion of study participants, include more comorbid patients, and focus on longer-term follow-up using multiple indices of outcome. More research on combined pharmacological and psychotherapeutic interventions is also indicated.
多项定性研究和荟萃分析表明,心理治疗和药物干预对强迫症(OCD)有效。在本文中,我们报告了一项对1980年至2001年间发表的强迫症心理治疗和药物治疗研究的多维度荟萃分析,研究了一系列此前未进行过荟萃分析的变量,包括排除率和排除标准、治疗后改善或康复的患者百分比、治疗后的平均症状学表现以及长期结果。这些额外的指标为现有数据的优势和局限性及其对临床实践的影响提供了更细致入微的观点。行为疗法和认知行为疗法,以及一系列药物干预措施,能使普通患者有显著改善,其中个体心理治疗、氯米帕明和其他5-羟色胺再摄取抑制剂在多个指标上表现最佳。然而,即使经过充分的治疗过程,强迫症症状仍维持在中等水平,且对于任何一种治疗方式在1年及以后的疗效维持情况,均没有可重复的数据。未来的研究应追踪研究参与者的招募和排除情况,纳入更多合并其他疾病的患者,并使用多种结果指标关注长期随访。还需要对联合药物和心理治疗干预进行更多研究。